SCHEMBL215785

SCHEMBL215785

Cc1cccc(N(C(=O)c2nc[nH]c2C(N)=O)c2nc3ccccc3[nH]2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.41
▸ MEN1 O00255 4/20 0.38
▸ KMT2A Q03164 4/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ MAPT P10636 1/20 0.38
▸ MAPK10 P53779 1/20 0.37
▸ LMNA P02545 4/20 0.37
▸ HTT P42858 3/20 0.37
▸ TP53 P04637 1/20 0.37
▸ PTBP1 P26599 1/20 0.37
▸ STAT3 P40763 1/20 0.37
▸ PAX8 Q06710 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ MPO P05164 1/20 0.36
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ LPAR2 Q9HBW0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL216070 0.89 POLB (0.47) POLBMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL216365 0.88 POLB (0.50) POLBMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL213760 0.88 POLB (0.39) POLBMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL216492 0.87 POLB (0.37) POLBMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL217227 0.87 POLB (0.37) POLBMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL214715 0.84 POLB (0.40) POLBKMT2ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL215596 0.83 POLB (0.38) POLBSMN1; SMN2ALDH1A1MAPTMAPK10
SCHEMBL216562 0.82 POLB (0.64) POLBMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL215133 0.82 POLB (0.38) POLBMEN1KMT2AALDH1A1MAPT
SCHEMBL214977 0.82 POLB (0.38) POLBSMN1; SMN2ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 — — US claimed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 — — US claimed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 — — EP claimed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 — — WO claimed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 — — US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 — — US disclosed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 — — EP disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 POLB 3464/4885MEN1 3504/4885KMT2A 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback